Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
APTO | US
0.02
6.75%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.39
0.37
0.39
0.36
Aptose Biosciences Inc. a clinical-stage biotechnology company discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253 which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib an orally administered and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies including chronic lymphocytic leukemia small lymphocytic lymphoma and various non-Hodgkin's lymphomas as well as AML and HR MDS. It has agreements with CrystalGenomics Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto Canada.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
52.0%1 month
54.5%3 months
77.4%6 months
65.0%-
-
67.84
-0.38
0.07
0.05
-
-
-40.85M
6.96M
6.96M
-
-
-
-
-694.13
0.14
1.37
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.06
Range1M
0.09
Range3M
0.33
Rel. volume
1.52
Price X volume
43.08K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Moleculin Biotech Inc | MBRX | Biotechnology | 2.67 | 7.59M | 3.29% | n/a | 3.00% |
Pulmatrix Inc | PULM | Biotechnology | 2.04 | 7.45M | 0.97% | n/a | 0.18% |
Cyclerion Therapeutics Inc | CYCN | Biotechnology | 2.9099 | 7.32M | 16.40% | n/a | 0.00% |
Orgenesis Inc | ORGS | Biotechnology | 1.53 | 7.30M | -27.49% | n/a | -84.02% |
Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 1.63 | 7.08M | 6.54% | n/a | 4.18% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.49 | 7.07M | 2.75% | n/a | 0.89% |
CDIO | CDIO | Biotechnology | 0.231 | 7.07M | 9.53% | n/a | 28.31% |
Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 4.68 | 7.05M | 23.16% | n/a | 0.00% |
Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 2.69 | 6.99M | 6.32% | n/a | -4.26% |
Adial Pharmaceuticals Inc | ADIL | Biotechnology | 1.07 | 6.85M | 5.94% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.05 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 67.84 | 15.55 | Expensive |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 77.36 | 72.80 | Par |
Debt to Equity | -0.38 | -1.23 | Expensive |
Debt to Assets | 0.07 | 0.25 | Cheaper |
Market Cap | 6.96M | 3.66B | Emerging |